Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nastech Pharmaceutical Co., P&G deal

PG ended a 2006 deal that granted it worldwide rights to NSTK's intranasal teriparatide

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE